Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Karunaratna, Nathasha
Jensen, Andrew
Wong, Shirley
Shapiro, Julia
Weickhardt, Andrew
Spain, Lavinia
Azad, Arun
Kwan, Edmond M.
Muthusamy, Arun
Torres, Javier
Parente, Phillip
Parnis, Francis
Goh, Jeffrey
Gibbs, Peter
Tran, Ben
Anton, Angelyn
机构：
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs47
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [41] Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).
    Mak, Blossom
    Lin, Hui-Ming
    Mahon, Kate Lynette
    Joshua, Anthony M.
    Stockler, Martin R.
    Gurney, Howard
    Parnis, Francis
    Zhang, Alison Yan
    Scheinberg, Tahlia
    Wittert, Gary
    Butler, Lisa
    Hoy, Andrew
    Meikle, Peter
    Horvath, Lisa
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [42] Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa Maria
    Bassi, Sunakshi
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [43] Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC).
    Pond, Gregory Russell
    Templeton, Arnoud J.
    Petrylak, Daniel Peter
    Fandi, Abderrahim
    Tombal, Bertrand F.
    Rosenthal, Mark
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] Opioid use in Veterans with metastatic castration-resistant prostate cancer
    Rasmussen, Kelli M.
    Yong, Christina
    Patil, Vikas
    Li, Catherine
    Sauer, Brian C.
    Halwani, Ahmad
    CANCER RESEARCH, 2020, 80 (16)
  • [45] Response evaluation criteria in PSMA PET/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer.
    Gafita, Andrei
    Djaileb, Loic
    Rauscher, Isabel
    Fendler, Wolfgang P.
    Hadaschik, Boris A.
    Rowe, Steven P.
    Herrmann, Ken
    Calais, Jeremie
    Rettig, Matthew
    Eiber, Matthias
    Weber, Manuel
    Benz, Matthias R.
    Farolfi, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 45 - 45
  • [46] Assessment of Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-Resistant Prostate Cancer
    Gafita, A.
    Djaileb, L.
    Rauscher, I.
    Fendler, W. P.
    Hadaschik, B.
    Czernin, J.
    Herrmann, K.
    Rowe, S. P.
    Calais, J.
    Rettig, M.
    Eiber, M.
    Weber, M.
    Benz, M. R.
    Farolfi, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S544 - S545
  • [47] Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burden.
    Small, Eric Jay
    Saad, Fred
    Zheng, Ying
    Pan, Feng
    Mehra, Maneesha
    Lawson, Joe
    Hadaschik, Boris A.
    Uemura, Hiroji
    Lee, Ji Youl
    Mainwaring, Paul N.
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC)
    Petrylak, D.
    Kantoff, P.
    Mega, A.
    Stephenson, J.
    Vogelzang, N.
    Fleming, M.
    Blattman, S.
    Stambler, N.
    D'Ambrosio, P.
    Israel, R. J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 75 - 75
  • [49] Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial
    Lorente, D.
    De Velasco Oria, G. A.
    Carles, J.
    Gillessen, S.
    Fizazi, K.
    Joshua, A.
    Eisenberger, M.
    Sartor, O.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] Treatment of castration-resistant metastatic prostate cancer with [177Lu]PSMA radioligand
    Sundset, Rune
    Haugnes, Hege Sagstuen
    Perez, Alexander
    Engelsen, Ola
    Fosseide, Ida H. H.
    Castillejo, Miguel J.
    Bogsrud, Trond Velde
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2024, 144 (09)
12345